Aderhold, V. et al.: Frontale Hirnvolumenminderung durch Antipsychotika? In: Nervenarzt 86, S. 302-323, 2015

Bachmann, C.J. et al.: Antipsychotic Prescription in Children and Adolescents – An Analysis of Data from a German Statutory Health Insurance Company from 2005–2012. In: Deutsches Ärzteblatt 111, S. 25-34, 2014

Faraone, S.V. et al.: Effects of Stimulants of Hight and Weight: A Review of the Literature. In: Journal of the American Academy of Child and Adolescent Psychiatry 47, S. 994-1009, 2008

Gibbons, R, et al.: Early Evidence on the Effects of Regulators’ Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents. In: American Journal of Psychiatry 164, S. 1356-1363, 2007

Grau, K. et al.: Psychopharmakologie in der Kinder- und Jugendpsychiatrie in Deutschland: Off-label-Use und Zulassungen verfügbarer Fertigarzneimittel. In: Psychopharmakotherapie 22, S. 240-249, 2015

Hoffmann, F. et al.: Outpatient Treatment in German Adolescents with Depression: An Analysis of Nationwide Health Insurance Data. In: Pharmacoepidemiology and Drug Safety 21, 972-979, 2012

Hoffmann, F. et al.: Trends in Antidepressant Prescriptions for Children and Adolescents in Germany from 2005 to 2012. In: Pharmacoepidemiology and Drug Safety, 23, S. 1268-72, 2014

Ivarsson, T. et al.: The Place of and Evidence for Serotonin Reuptake Inhibitors (SRIs) for Obsessive Compulsive Disorder (OCD) in Children and Adolescents: Views Based on a Systematic Review and Meta-Analysis. In: Psychiatry Research 227, S. 93-103, 2015

James, A.C.: Prescribing Antipsychotics for Children and Adolescents. In: Advances in Psychiatric Treatment 16, S. 63–75, 2010

Jensen, P.S. et al.: Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and Applications for Primary Care Providers. In: Journal of Developmental and Behavioral Pediatrics 22, S. 60-73, 2001

Le Noury, J. et al.: Restoring Study 329: Efficacy and Harms of Paroxetine and Imipramine in Treatment of Major Depression in Adolescence. In: British Medical Journal 351, S. 4320, 2015

Lu, C.Y. et al.: Changes in Antidepressant Use by Young People and Suicidal Behavior after FDA Warnings and Media Coverage: Quasi-experimental Study. In: British Medical Journal 348, g3596, doi: 10.1136/bmj.g3596, 2014

March, J.S. et al.: The Treatment for Adolescents With Depression Study (TADS) – Long-term Effectiveness and Safety Outcomes. In: Archives of General Psychiatry 64, S. 1132-1144, 2007

Miller, M. et al.: Antidepressant Dose, Age, and the Risk of Deliberate Self-harm. In: JAMA Intern Med. 174, S. 899-909, 2014

Persico, A,M. et al.: Unmet Needs in Paedeatric Psychopharmacology: Present Scenario and Future Perspectives. In: European Neuropsychopharmacology 25, S. 1513-1531, 2015

Shaw, P. et al.: Psychostimulant Treatment and the Developing Cortex in Attention-Deficit/Hyperactivity Disorder. In: American Journal of Psychiatry 166, S. 58-63, 2009

Swanson, J.M. et al.: Effects of Stimulant Medication on Growth Rates: Across 3 Years in the MTA follow-up. In: Journal of the American Academy of Child and Adolescent Psychiatry 46, S. 1015-1027, 2007

Wuppermann, A. et al: Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) bei Kindern und Jugendlichen in der ambulanten Versorgung in Deutschland. Teil 2 - Zusammenhang zwischen ADHS-Diagnose- und Medikationsprävalenzen und dem Einschulungsalter. Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi). Versorgungsatlas-Bericht Nr. 15/11. Berlin, 2015.

Wang, G.-J. et al.: Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder. In: PLoS ONE 8, e63023, 2013

Villemonteix, T. et al.: Grey Matter Volumes in Treatment Naïve vs. Chronically Treated Children with Attention Deficit/Hyperactivity Disorder:
A Combined Approach. In: European Neuropsychopharmacology, 25, S. 1118-1127, 2015